ESR1 and breast carcinoma: Our data show specific staining for ERβ1 isoform in TNBC specimens, a finding consistent with other recent reports that both ERβ1 and ER coregulator SRAP are predictive biomarkers of tamoxifen-response/benefit in women with ERα-negative breast cancer [17, 70].